eligibility_summary
Adults 18–75 with CD20+ DLBCL, relapsed/refractory after ≥1 prior systemic line (incl anti‑CD20), ECOG 0–2, measurable disease, adequate labs, WOCBP negative test + contraception. Exclude double/triple‑hit, recent (<14 d) therapy/surgery/live vaccine/IV antibiotics, investigational drug ≤3 mo, unresolved AEs/drug allergy, ASCT ≤3 mo or prior allo‑SCT, VTE w/o prophylaxis, concurrent anticancer Rx, malignancy ≤5 y, active HBV/HCV/HIV/serious infection, malabsorption, severe bleeding, stroke/ICH ≤6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06033820 tests ZR2-ICE (zanubrutinib + lenalidomide + rituximab/ifosfamide/carboplatin/etoposide) in relapsed/refractory DLBCL. Mechanisms/types: • Zanubrutinib: oral small-molecule Bruton’s tyrosine kinase (BTK) inhibitor, blocks B-cell receptor signaling to reduce malignant B-cell survival/proliferation. • Lenalidomide: oral immunomodulatory drug (IMiD), binds cereblon to degrade IKZF1/3, enhances T/NK-cell cytotoxicity and anti-tumor immunity, with direct lymphoma effects. • Rituximab: anti-CD20 monoclonal antibody, mediates ADCC/CDC and apoptosis of CD20+ B cells. • Ifosfamide: alkylating agent causing DNA crosslinks. • Carboplatin: platinum DNA crosslinker. • Etoposide: topoisomerase II inhibitor causing DNA strand breaks. Targeted cells/pathways: CD20+ malignant B cells, BCR/BTK pathway, cereblon/IKZF axis and immune effector function, DNA damage and apoptotic pathways.